GYKI 16084

Drug Profile

GYKI 16084

Alternative Names: Uroflux

Latest Information Update: 11 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IVAX Drug Research Institute
  • Class Pyridazines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 24 Feb 2004 IVAX has completed a phase II trial in Benign prostatic hyperplasia in Hungary
  • 18 Jun 2001 Phase-II clinical trials for Benign prostatic hyperplasia in Hungary (Unknown route)
  • 14 Jan 2000 Phase-I clinical trials for Benign prostatic hyperplasia in Hungary (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top